GE Healthcare of Chalfont St. Giles, U.K., is highlighting results from a large, randomized clinical trial that show the company's Visipaque contrast agent is associated with lower risk of contrast-induced nephropathy (CIN) in high-risk elderly patients.
The trial was conducted at the Shenyang General Hospital in China. It found that Visipaque (iodixanol), an iso-osmolar contrast medium, carries less risk of CIN than low-osmolar iopromide. Results were presented at European Association of Percutaneous Cardiovascular Interventions (EAPCI) conference in Paris.
Data from 1,656 patients (828 in each arm) were available for analysis. The study tracked the mean change from baseline in serum creatinine on the third day after contrast medium administration, along with the incidence of CIN, defined as an increase in serum creatinine of at least 0.5 mg/dL, within the three-day period.
The serum creatinine increases from baseline to day 3 were not statistically significant in the Visipaque group, but were statistically significant (p < 0.001) in the iopromide group. The relative increase in serum creatinine was significantly lower for Visipaque (0.05 ± 0.03 mg/dL, or 2.5%) than for iopromide (0.25 ± 0.27 mg/dL, or 14.1%; p < 0.001), GE said.
Related Reading
GE launches CT scanner in Europe, May 25, 2010
GE hits healthymagination goals, May 24, 2010
GE touts ADMIRE-HF trial results, May 21, 2010
GE partners with CardioDx on diagnostics, May 13, 2010
GE's German IT unit chooses Matrox boards, May 12, 2010
Copyright © 2010 AuntMinnie.com
